Corporate Board Profile
Tech Score: 22/100
2 mention(s) identify JEROME B. ZELDIS, MD, PHD as having software/technology expertise.
| Company | Filing Date | Evidence | Reason |
|---|---|---|---|
| SOLIGENIX, INC. | 2022-08-05 | Jerome B. Zeldis, MD, PhD has been a director since June 2011. Dr. Zeldis is currently Chief Medical Officer and President of Clinical Research, Drug Safety and Regulatory of Sorrento Therapeutics, Inc. He is also Chief Medical Officer and Principal at Celularity, Inc. Previously, Dr. Zeldis was Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation, a publicly traded, fully integrated biopharmaceutical company. He was employed by Celgene Corporation from 1997 to 2016. From September 1994 to February 1997, Dr. Zeldis worked at Sandoz Research Institute and the Janssen Research Institute in both clinical research and medical development. He has been a board member of several biotechnology companies and is currently on the boards of Metastat, Inc., PTC Therapeutics Inc., BioSig Technologies, Inc., the Castleman’s Disease Organization, Alliqua, Inc and Nexgel, Inc. He has previously served on the boards of the NJ Chapter of the Arthritis Foundation and PTC Therapeutics, Inc. Additionally, he has served as Assistant Professor of Medicine at the Harvard Medical School (from July 1987 to September 1988), Associate Professor of Medicine at University of California, Davis from (September 1988 to September 1994), Clinical Associate Professor of Medicine at Cornell Medical School (January 1995 to December 2003) and Professor of Clinical Medicine at the Robert Wood Johnson Medical School (July 1998 to June 2010). Dr. Zeldis received a BA and an MS from Brown University, and an MD, and a PhD in Molecular Biophysics and Biochemistry from Yale University. Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and in Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. | Dr. Zeldis holds a PhD in Molecular Biophysics and Biochemistry from Yale University, indicating a strong technical and scientific background that likely includes programming skills. |
| SOLIGENIX, INC. | 2023-08-07 | Dr. Zeldis received a BA and an MS from Brown University, and an MD, and a PhD in Molecular Biophysics and Biochemistry from Yale University. | Dr. Zeldis holds a PhD in Molecular Biophysics and Biochemistry, which is a technical field closely related to software and programming skills. |
| Filing Date | Source Excerpt |
|---|---|
| 2016-05-02 | Jerome B. Zeldis, MD, PhD has been a director since June 2011... The Compensation Committee is comprised of Dr. Rubin (Chair), Dr. Brughera and Dr. Zeldis... The Nominating and Corporate Governance Committee is comprised of Dr. Zeldis (Chair), Mr. Brownlie and Mr. Lapointe... Compensation of Directors: Jerome B. Zeldis Fees Earned Paid in Cash $50,000, Option Awards $30,000, Total $80,000. |
| 2017-04-28 | Jerome B. Zeldis, MD, PhD has been a director since June 2011... The Compensation Committee is comprised of Dr. Rubin (Chair), Dr. Brughera and Dr. Zeldis... The Nominating and Corporate Governance Committee is comprised of Dr. Zeldis (Chair), Mr. Brownlie and Mr. Lapointe... The following table contains information concerning the compensation of the non-employee directors during the fiscal year ended December 31, 2016. Jerome B. Zeldis Fees Earned Paid in Cash $50,000 Option Awards $30,000 Total $80,000. |
| 2018-08-10 | Jerome B. Zeldis, MD, PhD 68 Director |
| 2019-07-26 | Jerome B. Zeldis, MD, PhD has been a director since June 2011. Our Board of Directors has a Compensation Committee, which is comprised of Dr. Rubin (Chair), Mr. Pearson and Dr. Zeldis. Our Board of Directors has a Nominating and Corporate Governance Committee, which is comprised of Dr. Zeldis (Chair), Mr. Brownlie and Mr. Lapointe. The following table contains information concerning the compensation of the non-employee directors during the year ended December 31, 2018. Jerome B. Zeldis: Fees Earned Paid in Cash: $50,000, Option Awards: $30,000, Total: $80,000. |
| 2020-08-07 | Jerome B. Zeldis, MD, PhD has been a director since June 2011. ... Our Board of Directors has a Compensation Committee, which is comprised of Dr. Rubin (Chair), Mr. Lapointe and Dr. Zeldis. ... Our Board of Directors has a Nominating and Corporate Governance Committee ("Nominating Committee"), which is comprised of Dr. Zeldis (Chair), Mr. Lapointe and Ms. Parks. |
| 2021-08-10 | Jerome B. Zeldis, MD, PhD has been a director since June 2011. ... Our Board of Directors has a Compensation Committee, which is comprised of Dr. Rubin (Chair), Mr. Lapointe and Dr. Zeldis. ... Our Board of Directors has a Nominating and Corporate Governance Committee ("Nominating Committee"), which is comprised of Dr. Zeldis (Chair), Mr. Lapointe and Ms. Parks. ... Compensation of Directors table shows Jerome B. Zeldis earned $50,000 in cash and $30,000 in option awards for a total of $80,000 in 2020. |
| 2022-08-05 | Jerome B. Zeldis, MD, PhD has been a director since June 2011. Dr. Zeldis is currently Chief Medical Officer and President of Clinical Research, Drug Safety and Regulatory of Sorrento Therapeutics, Inc. He is also Chief Medical Officer and Principal at Celularity, Inc. Previously, Dr. Zeldis was Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation, a publicly traded, fully integrated biopharmaceutical company. He was employed by Celgene Corporation from 1997 to 2016. From September 1994 to February 1997, Dr. Zeldis worked at Sandoz Research Institute and the Janssen Research Institute in both clinical research and medical development. He has been a board member of several biotechnology companies and is currently on the boards of Metastat, Inc., PTC Therapeutics Inc., BioSig Technologies, Inc., the Castleman’s Disease Organization, Alliqua, Inc and Nexgel, Inc. He has previously served on the boards of the NJ Chapter of the Arthritis Foundation and PTC Therapeutics, Inc. Additionally, he has served as Assistant Professor of Medicine at the Harvard Medical School (from July 1987 to September 1988), Associate Professor of Medicine at University of California, Davis from (September 1988 to September 1994), Clinical Associate Professor of Medicine at Cornell Medical School (January 1995 to December 2003) and Professor of Clinical Medicine at the Robert Wood Johnson Medical School (July 1998 to June 2010). Dr. Zeldis received a BA and an MS from Brown University, and an MD, and a PhD in Molecular Biophysics and Biochemistry from Yale University. Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and in Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. |
| 2023-08-07 | Dr. Zeldis received a BA and an MS from Brown University, and an MD, and a PhD in Molecular Biophysics and Biochemistry from Yale University. |
| 2024-04-29 | Jerome B. Zeldis, MD, PhD has been a director since June 2011. Dr. Zeldis retired as Executive Vice President, Research and Development of Neximmune. The Compensation Committee includes Dr. Zeldis. The Nominating and Corporate Governance Committee is chaired by Dr. Zeldis. |
Data sourced from SEC filings. Last updated: 2025-12-06